Special Issue

HIV Elimination as the Goal by 2030

Message from the Guest Editor

Our society constantly faces important public health crises, potentially affecting millions of people and, often, many lives lost. The HIV/AIDS epidemic is one of these crises, mobilizing the global community over the last forty years. Over that period, huge progress has been made to reduce the burden of the disease by improving the diagnosis as well as the access to more potent antiretroviral drugs and engaging in better monitoring of this life-long treatment. Building on these successes, UNAIDS has launched ambitious initiatives and targets as the 90-90-90 targets, and designed transformative actions to end the global AIDS epidemic by 2030. Although the impressive scale-up of antiretroviral treatments over the past 20 years, especially in the most affected regions of the world, makes such a goal achievable, there are still important challenges. In this Special Issue, I welcome your recent research and results that present linkages with this ambitious goal of HIV/AIDS elimination by the next decade. I am convinced that this Special Issue will help inform the global community about the ongoing successes and the remaining challenges towards achieving this goal.

Guest Editor

Dr. Avelin F. Aghokeng Institut de Recherche pour le Développement (IRD), Marseille, French

Deadline for manuscript submissions

closed (20 July 2023)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/121095

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAq, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).